Trials / Completed
CompletedNCT05327660
CO Monitoring for Tobacco Cessation in Quitlines
Remote Carbon Monoxide Monitoring and Incentives for Tobacco Cessation in Quitlines
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 229 (actual)
- Sponsor
- Consumer Wellness Solutions · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The present study is a 3-arm randomized controlled pilot study. Participants who call the Maryland Tobacco Quitline and are eligible for study participation are randomized to receive quitline tobacco cessation treatment as usual (TAU), TAU plus remote carbon monoxide (CO) monitoring via smartphone app, or TAU plus remote carbon monoxide monitoring plus incentives vis smartphone app. The investigators hypothesize that remote CO monitoring will be feasible and acceptable to deliver in the quitline setting, will increase treatment engagement, and will increase tobacco cessation and treatment satisfaction rates.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Quitline Treatment as Usual (TAU) | Quitline TAU is services provided by the state quitline and includes phone coaching, nicotine replacement, supplemental materials (e.g., text messaging, online content). |
| COMBINATION_PRODUCT | Remote Carbon Monoxide (CO) Monitoring | Remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor. |
| COMBINATION_PRODUCT | Incentivized Remote CO Monitoring | Incentivized remote CO monitoring includes a smartphone app and a remote carbon monoxide monitor. The app tracks and prompts daily use of the CO monitor and delivers small monetary incentives for each use of the CO monitor. |
Timeline
- Start date
- 2021-12-31
- Primary completion
- 2022-11-01
- Completion
- 2022-11-01
- First posted
- 2022-04-14
- Last updated
- 2024-10-28
- Results posted
- 2024-10-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05327660. Inclusion in this directory is not an endorsement.